Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial

Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial

Background: Low-dose (LD) or intermediate-dose (MD) immune tolerance induction (ITI) is effective in children with severe hemophilia A (SHA) with high-titer inhibitors (HTIs) and is attractive in countries with economic constraints. However, high-quality evidence of their use is lacking. Objectives:...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhengping Li, Zekun Li, Xiaoling Cheng, Heng Zhang, Can Yang, Qian Xu, Zhenping Chen, Yingzi Zhen, Gang Li, Guoqing Liu, Wanru Yao, Min Zhou, Jiao Jin, Jie Huang, Yongjun Fang, Liangzhi Xie, Man-Chiu Poon, Runhui Wu
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
immune tolerance induction
intermediate dose
low dose
randomized clinical trial
severe hemophilia A
Online Access:http://www.sciencedirect.com/science/article/pii/S2475037924003340
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2475037924003340

Similar Items